Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590

Wakelee, Heather A.; Stephenson, Patricia; Keller, Steven M.; Wagner, Henry; Herskovic, Arnold; Komaki, Ritsuko; Marks, Randolph S.; Perry, Michael C.; Livingston, Robert B.; Johnson, David H.

doi:10.1016/j.lungcan.2004.11.007

Cited by 68 publications

(28 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As more effective systemic therapies are developed and more recent data using modern radiation fractionation become available, updated techniques and equipment have supported adjuvant treatment modalities including PORT because the treatment-related mortality is much lower than expected from the older trials [24,25].…”

Section: Commentmentioning

confidence: 99%

Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery

Lim

Lee

et al. 2014

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

Section: Commentmentioning

confidence: 99%

Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery

Lim

Lee

et al. 2014

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…7 The authors of that report suggested that the addition of PORT may have had an adverse effect by virtue of acute or delayed radiation effects, such as radiation pneumonitis or cardiotoxicity. Heart disease mortality accounts for the major component of late radiation-induced toxicity 8,9 ; the discrepancy between an increase in local control and a decrease in survival for patients receiving PORT warrants further investigation.…”

mentioning

confidence: 99%

The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy

Lally

Detterbeck

Geiger

et al. 2007

Cancer

106

View full text Add to dashboard Cite

A range of flat hot‐compacted single‐polymer composite panels made from oriented polypropylene and polyethylene with differing dynamic modulus and damping capacity were freely suspended and subjected to mechanical excitation, allowing their acoustic frequency response over the audio bandwidth to be measured. The audio response over selected bands was correlated with the dynamic modulus and damping capacity measured in bending in these materials and compared with the response of a traditional composite material, namely, carbon‐fiber‐reinforced epoxy resin. Low damping and high dynamic modulus were found to result in relatively high output levels from the hot‐compacted flat panels, which contrasted with the results previously measured on a traditional cone‐shaped speaker made from a hot‐compacted polypropylene material, which found high damping to be advantageous. The results of the current study on flat panels are explained in terms of mechanical impedance of the panels and their corresponding efficiency. It was concluded that the best flat‐panel audio response came from compacted polyethylene sheets, which combined high stiffness, low density, and a low level of damping. © 2005 Wiley Periodicals, Inc. J Appl Polym Sci, 2006

show abstract

“…The late toxic effects of administering concurrent therapy in this population are not clear. Death from intercurrent disease at 4 years was 15.4% for patients who received PORT and 18.4% for patients treated with combined therapy (38). Although these figures are significantly different than the expected rate of intercurrent disease (based on mortality rates for age-and gender-matched controls derived from U.S. vital statistics and corrected for smoking status), the trial did not have an appropriate (no PORT) control arm.…”

Section: Adjuvant Trials Including Chemotherapy and Radiotherapymentioning

confidence: 90%

Localized Non–Small Cell Lung Cancer: Adjuvant Radiotherapy in the Era of Effective Systemic Therapy

Bogart

Aronowitz

2005

Clinical Cancer Research

View full text Add to dashboard Cite

Investigators in Europe, Canada, and the United States recently established a definitive role for adjuvant systemic chemotherapy following resection of early-stage non^small cell lung cancer (NSCLC). This was no small accomplishment, as upward of 20 randomized trials had previously been conducted. The role of postoperative radiotherapy (PORT) has been studied with far less vigor in the modern era. A1998 meta-analysis of randomized trials suggesting that PORTwas detrimental to survival included studies of doubtful quality.The value of PORTshould be considered in the same context as recent chemotherapy trials. Advances in imaging have improved the accuracy of staging, patient selection, and target definition. Modern dosimetry and accelerator technologies have advanced the capacity to deliver radiation to the target with less tissue toxicity. Evolving philosophies in dosing and fractionation should improve the therapeutic ratio. Finally, it is reasonable to assume that the importance of local control will be enhanced in the setting of better systemic therapies.We will review the data on PORTand address critical issues in the design of trials to assess the role of modern radiotherapy in the integrated approach to management of earlystage NSCLC.

show abstract

Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590

Cited by 68 publications

References 38 publications

Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery

Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery

The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy

Localized Non–Small Cell Lung Cancer: Adjuvant Radiotherapy in the Era of Effective Systemic Therapy

Contact Info

Product

Resources

About